-+ 0.00%
-+ 0.00%
-+ 0.00%
Yuandong Biotech announced that EP-0226 tablets, a Class 1 innovative chemical drug jointly developed by the company, the Shanghai Institute of Pharmaceutical Sciences of the Chinese Academy of Sciences and the Zhongke Zhongshan Pharmaceutical Innovation Research Institute, are conducting a phase II/III clinical trial of efficacy and safety in patients with post-herpes zoster neuralgia in China, comparing placebo and pregabalin capsules, and recently completed the first case of patient administration. The study seamlessly connected phase II and phase III. The first phase was aimed at initially evaluating the pharmacokinetic characteristics, efficacy and safety of different doses of EP-0226 tablets and recommending the optimal dosage, while the second phase aimed to confirm the efficacy and safety of the recommended dose. As of the disclosure date, the first phase had completed administration of the first test subject, and the recruitment and enrolment of other subjects was in progress.
Share
Listen to the news
Yuandong Biotech announced that EP-0226 tablets, a Class 1 innovative chemical drug jointly developed by the company, the Shanghai Institute of Pharmaceutical Sciences of the Chinese Academy of Sciences and the Zhongke Zhongshan Pharmaceutical Innovation Research Institute, are conducting a phase II/III clinical trial of efficacy and safety in patients with post-herpes zoster neuralgia in China, comparing placebo and pregabalin capsules, and recently completed the first case of patient administration. The study seamlessly connected phase II and phase III. The first phase was aimed at initially evaluating the pharmacokinetic characteristics, efficacy and safety of different doses of EP-0226 tablets and recommending the optimal dosage, while the second phase aimed to confirm the efficacy and safety of the recommended dose. As of the disclosure date, the first phase had completed administration of the first test subject, and the recruitment and enrolment of other subjects was in progress.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending